Administrative Supplements for NIAID Regional Biocontainment Laboratories (RBL)

项目摘要/摘要： 正在进行的COVID大流行表明需要最先进的设施和基础设施来 加强我们对后续流行病和/或大流行的准备。乔治梅森大学(GMU)， 利用区域生物遏制实验室，指定为生物医学研究实验室 (BRL)，建立了一个生物医学研究计划，重点放在新出现的和重新出现的 可能导致严重人类和动物疾病的新出现的病毒和细菌病原体。这个 目前在BRL中调查的最大流行问题的特定病毒病原体家族是： Togaviridae、Bunyaviridae、Coronaviridae和Flaviridae。五个系的几名教职员工 GMU(系统生物学、生物学、生物工程、生物化学、全球和社区健康)以及 外部合作者进行基础和应用研究，包括致病性、感染性 机制，以及诊断、疫苗和治疗学的发展。 GMU的传染病投资组合在21财年为880万美元，预计在21财年将至少增长3倍 接下来的五年。为了实现这一目标，GMU领导层正在对新教师进行积极的战略投资 招聘和种子资金，以及创造更广泛的机会进入BRL。超过244篇同行评议文章 自2010年以来，GMU的调查人员发表了关于传染病的研究报告。 BRL的工作人员致力于支持GMU的教职员工、学生和他们的合作者开发新的 大流行防备的翻译解决方案。具有翻译承诺的研究包括1) 开发额外的候选疫苗，提供对多种毒株的广谱保护 甲型病毒或冠状病毒，2)基于宿主的疗法的评估，这些疗法在体外证明了广泛的- 对甲型病毒(VEEV、EEEV、WeeV、CHIKV)、布尼亚病毒(RVFV)和 冠状病毒(SARS-CoV-2)在啮齿动物和非啮齿动物模型(包括雪貂)中的感染；3) 新的平台技术，包括基于胞外囊泡(EV)的免疫调节剂和报告病毒 这有助于快速筛选临床和非临床样本中的中和抗体。 我们的高密封性设施由一组运营和技术人员支持，为 广泛的内部和外部研究人员在体外和体内进行研究和开发 新出现和重新出现的病毒和细菌病原体。GMU正在申请资金以补充 由20国集团资助的家长奖，“设施和建筑系统升级支持梅森生物医学 研究实验室“，以解决额外的具体仪器和设施的差距，以支持 创建现代、全面、灵活和有弹性的临床前生物医学研究管道，以解决 国家和全球大流行防备。

Project Summary/Abstract: The ongoing COVID pandemic has demonstrated the need for state-of-the-art facilities and infrastructure to improve our preparedness for subsequent epidemics and/or pandemics. George Mason University (GMU), leveraging the Regional Biocontainment Laboratory, designated as the Biomedical Research Laboratory (BRL), has established a biomedical research program with a strong emphasis on newly emerging and re- emerging viral and bacterial pathogens with the potential to cause severe human and animal diseases. The specific viral pathogen families of greatest pandemic concern currently investigated in the BRL are: Togaviridae, Bunyaviridae, Coronaviridae, and Flaviviridae. Several faculty members in five departments at GMU (Systems Biology, Biology, Bioengineering, Biochemistry, and Global and Community Health) as well as external collaborators conduct research on basic and applied research to include pathogenicity, infection mechanisms, and development of diagnostics, vaccines and therapeutics. The infectious disease portfolio at GMU was $8.8 million in FY21 and is expected to grow by at least 3X in the next five years. To realize this goal, GMU leadership is making aggressive, strategic investments in new faculty hires and seed funding, as well as creating broader access to the BRL. More than 244 peer-reviewed articles on infectious diseases research have been published by GMU investigators since 2010. The BRL staff is dedicated to supporting GMU faculty, students, and their collaborators to develop new translational solutions for pandemic preparedness. Research with translational promise includes 1) development of additional vaccine candidates that confer broad-spectrum protection against multiple strains of alphaviruses or coronaviruses, 2) evaluation of host-based therapeutics that have demonstrated in vitro broad- spectrum efficacy against alphaviruses (VEEV, EEEV, WEEV, CHIKV), bunyaviruses (RVFV) and coronaviruses (SARS-CoV-2) in rodent and nonrodent animal models including ferrets, and 3) development of new platform technologies including extracellular vesicle (EV)-based immunomodulators and reporter viruses that can facilitate rapid screening of clinical and nonclinical samples for neutralizing antibodies. Our high containment facility supported by a team of operations and technical staff, creates opportunities for a broad base of internal and external investigators to conduct in vitro and in vivo research and development on newly emerging and re-emerging viral and bacterial pathogens. GMU is requesting funds to supplement the funded G20 parent award, “Facility and Building System Upgrades Support for the Mason Biomedical Research Laboratory” to resolve additional specific instrumentation and facility gaps that will support the creation of a modern, comprehensive, agile and resilient preclinical biomedical research pipeline to address national and global pandemic preparedness.